Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for Cidara Therapeutics in a report issued on Wednesday, June 18th. HC Wainwright analyst S. Nik anticipates that the biotechnology company will post earnings per share of ($2.11) for the quarter. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Cidara Therapeutics' current full-year earnings is ($8.74) per share. HC Wainwright also issued estimates for Cidara Therapeutics' Q3 2025 earnings at ($1.40) EPS, Q4 2025 earnings at ($1.46) EPS, FY2025 earnings at ($6.43) EPS, FY2026 earnings at ($6.03) EPS and FY2027 earnings at ($6.53) EPS.
Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($1.66) earnings per share for the quarter, topping analysts' consensus estimates of ($5.45) by $3.79.
CDTX has been the topic of a number of other research reports. Citizens Jmp started coverage on Cidara Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $46.00 price target on the stock. JMP Securities restated a "market outperform" rating and set a $47.00 price objective on shares of Cidara Therapeutics in a research report on Monday, June 2nd. Cantor Fitzgerald restated an "overweight" rating on shares of Cidara Therapeutics in a research report on Tuesday, June 10th. Needham & Company LLC raised their price objective on Cidara Therapeutics from $36.00 to $54.00 and gave the stock a "buy" rating in a research report on Monday. Finally, Citigroup started coverage on Cidara Therapeutics in a research report on Wednesday, March 12th. They set an "outperform" rating for the company. One research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Cidara Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $53.71.
View Our Latest Stock Report on CDTX
Cidara Therapeutics Stock Performance
CDTX traded down $1.30 during trading on Monday, reaching $48.03. The company had a trading volume of 1,937,866 shares, compared to its average volume of 152,027. The firm's 50-day simple moving average is $24.44 and its 200 day simple moving average is $22.70. The company has a market cap of $602.78 million, a price-to-earnings ratio of -1.63 and a beta of 0.79. Cidara Therapeutics has a 12-month low of $10.14 and a 12-month high of $56.83.
Institutional Investors Weigh In On Cidara Therapeutics
Institutional investors have recently made changes to their positions in the company. Millennium Management LLC lifted its holdings in shares of Cidara Therapeutics by 158.4% during the 4th quarter. Millennium Management LLC now owns 35,960 shares of the biotechnology company's stock valued at $967,000 after buying an additional 22,041 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Cidara Therapeutics in the 4th quarter valued at approximately $342,000. OMERS ADMINISTRATION Corp bought a new position in shares of Cidara Therapeutics in the 4th quarter valued at approximately $339,000. Vivo Capital LLC bought a new position in shares of Cidara Therapeutics in the 4th quarter valued at approximately $18,026,000. Finally, Schonfeld Strategic Advisors LLC raised its stake in shares of Cidara Therapeutics by 154.1% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 49,557 shares of the biotechnology company's stock valued at $1,332,000 after acquiring an additional 30,057 shares in the last quarter. 35.82% of the stock is currently owned by institutional investors and hedge funds.
Cidara Therapeutics Company Profile
(
Get Free Report)
Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
Featured Stories
Before you consider Cidara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cidara Therapeutics wasn't on the list.
While Cidara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
